| Preclinical modeling of combination treatments: fantasy or requirement? | |
| | |
MedLine Citation:
|
PMID: 16382044 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Combination chemotherapy is considered the "norm" in cancer chemotherapy. While the development of classical combination regimens took into account factors such as single-agent activity, different toxicity profiles, and advantageous pharmacology of the component drugs, in the era of targeted therapies there are additional considerations such as new mechanisms of resistance due to modulation of pathway dependence. Since it is not feasible to test all of the possible combinations clinically, some method for preclinically identifying and prioritizing promising combinations is necessary. While in vivo animal models can be used for safety testing and some pharmacokinetics, even they can quickly become prohibitively resource intensive for the purpose of efficacy determinations. Therefore, factors such as biologic rationale, reliable in vitro results in more than one tumor type, achievable in vivo pharmacology, and selectivity of primary tumor cell activity become important in the evaluation of potential combination regimens. |
| | |
Authors:
|
Shannon Decker; Edward A Sausville |
Related Documents
:
|
22781694 - Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. 22548724 - Induction of epithelial-mesenchymal transition by transforming growth factor β 22835954 - Synergic effect of photodynamic therapy using talaporfin sodium with conventional antic... 22548924 - Diffusion tensor and perfusion imaging of brain tumors in high-field mr imaging. 12230954 - Effects of retinoic acid on metastasis and its related proteins in gastric cancer cells... 1317744 - Effects of alprazolam on the development of mtv-induced mammary tumors in female mice u... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Annals of the New York Academy of Sciences Volume: 1059 ISSN: 0077-8923 ISO Abbreviation: Ann. N. Y. Acad. Sci. Publication Date: 2005 Nov |
Date Detail:
|
Created Date: 2005-12-29 Completed Date: 2006-06-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7506858 Medline TA: Ann N Y Acad Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 61-9 Citation Subset: IM |
Affiliation:
|
University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Disease Models, Animal Drug Screening Assays, Antitumor / methods Humans Models, Biological Neoplasms / drug therapy* Signal Transduction |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Targeting ligand cleavage to inhibit the ErbB pathway in cancer.
Next Document: Mechanisms of trastuzumab resistance and their clinical implications.